NeurologyRights Deal
Orelabrutinib (BTK Inhibitor) for Multiple Sclerosis; New Rights Deal & Expected Trial Push
October 2025
6 min read
What Happened
In October 2025, Zenas Biopharma acquired global rights to develop Orelabrutinib for MS and other indications.
Why It Matters
Orelabrutinib is a BTK-inhibitor, part of the newer generation of immunomodulatory therapies aiming to treat MS more precisely than older immunosuppressants. With Zenas now holding global rights, a global development push is likely; meaning potential Phase 2/3 trials soon. For Kitsa, this signals a pipeline renewal in neuro-immunology.
What to Watch
As development expands, expect:
- •IND filings
- •Multi-site trials (possibly including international sites)
- •Opportunities for patient recruitment networks
- •Need for robust trial-management frameworks
This could be a high-visibility MS program worth tracking.